LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Home・Lista de Ações・Kura Oncology Inc

Kura Oncology Inc

Abrir

SetorSaúde

8.67 -0.12

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

8.6

Máximo

9.04

Indicadores-chave
By Trading Economics
Rendimento	7.7M -73M
Vendas	929K 18M
EPS	-0.828
Margem de lucro	-401.495
Funcionários	260
EBITDA	7.4M -78M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+224.6% upside

Dividendos
By Dow Jones
Próximos Ganhos	6 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-42M 802M
Abertura anterior	8.79
Fecho anterior	8.67

Sentimento de Notícias

By Acuity

50%

154 / 344 Ranking em Healthcare

Kura Oncology Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

3 de jun. de 2026, 23:22 UTC

Ganhos

Grandes Movimentos do Mercado

Broadcom Shares Slide Despite Jump in 2Q Revenue on AI Chip Demand -- Update

3 de jun. de 2026, 23:09 UTC

Ações em Alta

Stocks to Watch: Broadcom, CrowdStrike, PVH, Petco

3 de jun. de 2026, 20:51 UTC

Ganhos

Costco Reports 15% Sales Growth in May

3 de jun. de 2026, 20:43 UTC

Ganhos

Broadcom 2Q Revenue Climbs on AI Chip Demand

3 de jun. de 2026, 23:48 UTC

Conversa de Mercado

Nikkei May Fall Amid Renewed Concerns About Iran Conflict -- Market Talk

3 de jun. de 2026, 23:48 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

3 de jun. de 2026, 23:35 UTC

Conversa de Mercado

Oil Futures Fall on Possible Technical Correction -- Market Talk

3 de jun. de 2026, 23:15 UTC

Conversa de Mercado

Ganhos

Five Below, Broadcom and Crowdstrike Fall Despite Solid Results -- Market Talk

3 de jun. de 2026, 22:08 UTC

Ações em Alta

After-Hours Stocks to Watch: CrowdStrike, Broadcom, Five Below -- WSJ

3 de jun. de 2026, 21:54 UTC

Conversa de Mercado

Correction to Oil Futures Rise on Concerns About U.S.-Iran Talks Article on June 1

3 de jun. de 2026, 21:18 UTC

Ganhos

Broadcom's Non-AI Semiconductor Revenue Rose 6% in 2Q, CEO Says

3 de jun. de 2026, 21:15 UTC

Ganhos

Broadcom CEO: Google Partnership Continues to Be 'Very Substantial'

3 de jun. de 2026, 21:13 UTC

Ganhos

Broadcom CEO Expects AI Semiconductor Revenue Growth to Continue in Fiscal 2028

3 de jun. de 2026, 21:13 UTC

Ganhos

Broadcom Continues to Expect AI Semiconductor Revenue of More Than $100B in 2027, CEO Says

3 de jun. de 2026, 21:12 UTC

Ganhos

Broadcom Expects AI Semiconductor Revenue of $56B This Year, CEO Says

3 de jun. de 2026, 21:09 UTC

Ganhos

Broadcom CEO: Networking Made Up Almost 40% of AI Revenue in 2Q

3 de jun. de 2026, 21:03 UTC

Ganhos

Broadcom Stock Falls After Earnings. Here's Why. -- Barrons.com

3 de jun. de 2026, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

3 de jun. de 2026, 20:43 UTC

Ganhos

CrowdStrike Stock Falls Despite Earnings Beat -- Barrons.com

3 de jun. de 2026, 20:39 UTC

Aquisições, Fusões, Aquisições de Empresas

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 4th Update

3 de jun. de 2026, 20:37 UTC

Aquisições, Fusões, Aquisições de Empresas

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 3rd Update

3 de jun. de 2026, 20:35 UTC

Ganhos

Broadcom Stock Falls Despite Record Results -- Barrons.com

3 de jun. de 2026, 20:21 UTC

Aquisições, Fusões, Aquisições de Empresas

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 2nd Update

3 de jun. de 2026, 20:17 UTC

Ganhos

Broadcom 2Q Semiconductor Solutions Revenue $15B >AVGO

3 de jun. de 2026, 20:17 UTC

Ganhos

Broadcom Sees 3Q Semiconductor Revenue From AI $16B >AVGO

3 de jun. de 2026, 20:15 UTC

Aquisições, Fusões, Aquisições de Empresas

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- Update

3 de jun. de 2026, 20:15 UTC

Ganhos

Broadcom 2Q Adj EPS $2.44 >AVGO

3 de jun. de 2026, 20:15 UTC

Ganhos

Broadcom 2Q EPS $1.91 >AVGO

3 de jun. de 2026, 20:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

3 de jun. de 2026, 20:15 UTC

Ganhos

Broadcom 2Q Rev $22.19B >AVGO

Comparação entre Pares

Variação de preço

Kura Oncology Inc Previsão

Preço-alvo

By TipRanks

224.6% parte superior

Previsão para 12 meses

Média 28.11 USD 224.6%

Máximo 40 USD

Mínimo 15 USD

Com base em 11 analistas de Wall Street que oferecem metas de preço de 12 meses para Kura Oncology Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

11 ratings

Comprar

Manter

Vender

Com base em 11 analistas que deram avaliações de ações para Kura Oncology Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

154 / 344 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.